EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 106.86

Change

+0.24 (+0.23)%

Market Cap

USD 0.70B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.53 (-1.18%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.82 (-0.81%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.33 (-1.39%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.16 (-1.22%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.05 (-0.91%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.21 (-0.88%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.13 (-0.99%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

+0.17 (+0.30%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.10 (-1.01%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.28 (-0.23%)

USD 12.26B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.24% 44% F 43% F
Dividend Return -16.59% 42% F 17% F
Total Return -17.83% 8% B- 9% A-
Trailing 12 Months  
Capital Gain -9.93% 11% F 17% F
Dividend Return -14.09% 50% F 15% F
Total Return -24.02% 6% D- 9% A-
Trailing 5 Years  
Capital Gain 15.00% 33% F 37% F
Dividend Return -11.58% 39% F 11% F
Total Return 3.43% 29% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 6.84% 53% F 54% F
Dividend Return 7.55% 55% F 55% F
Total Return 0.71% 66% D+ 43% F
Risk Return Profile  
Volatility (Standard Deviation) 9.42% 64% D 72% C
Risk Adjusted Return 80.21% 71% C- 75% C
Market Capitalization 0.70B 78% C+ 59% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike